Key inclusion criteria:

          -  Histologically confirmed NSCLC stage IB-IIIA (per AJCC 8th edition), deemed suitable
             for primary resection by treating surgeon, except for N2 and T4 tumors.

          -  Subject must be eligible for surgery and with a planned surgical resection in
             approximately 4-6 weeks (after the first dose of study treatment).

          -  A mandatory newly obtained tissue biopsy from primary site is required for study
             enrollment. An archival biopsy is also acceptable if obtained up to 5 months before
             first day of study treatment and if the subject did not go through antineoplastic
             systemic therapies between biopsy collection date and beginning of study treatment.

        Note: Aspirates will not be accepted.

        - Eastern Cooperative oncology group (ECOG) performance status of 0 or 1.

        Key exclusion criteria:

          -  Subjects with unresectable or metastatic disease.

          -  History of severe hypersensitivity reactions to monoclonal antibodies, which in the
             opinion of the investigator may pose an increased risk of serious infusion reaction

          -  Subjects who received prior systemic therapy (including chemotherapy, other
             anti-cancer therapies and any other antibody or drug specifically targeting T-cell
             co-stimulation or immune checkpoint pathways) in the past 3 years before screening

          -  Active autoimmune disease that has required systemic treatment in the past 2 years
             prior to randomization. Control of the disorder with replacement therapy is permitted

          -  Subject with suspected or proven immunocompromised state or infections

        Other protocol-defined inclusion/exclusion criteria may apply.